Intervention to Reduce Misused Inhaler and Insufficient Peak Inspiratory Flow in Hospitalized COPD Patients (MIPIF)

January 24, 2023 updated by: Gaël Grandmaison, Hôpital Fribourgeois

Misused Inhaler and Insufficient Peak Inspiratory Flow in Hospitalized COPD Patients Before and After Implementation of a Systematic Assessment and a Prescription Guide - a Quasi Experimental Study - MIPIF

The drug treatment of chronic obstructive pulmonary disease (COPD) is mainly based on inhaled therapy. This route of administration is limited by inhaler handling errors, insufficient inspiratory flow or inappropriate inhalers. According to the scientific literature, these limitations are extremely common in both outpatients and inpatients.

Our hypothesis is that the implementation of a standardised and systematic assessment of inhalers combined with a prescribing guide to help select a suitable inhaler will decrease the proportion of suboptimally used inhalers at discharge in patients hospitalised with a diagnosis of COPD.

To assess the effectiveness of our intervention, the investigators will compare the proportion of inhalers used suboptimally at hospital discharge between a control cohort before the implementation of our intervention and a cohort after the implementation of our intervention. Secondary outcomes include reasons for sub-optimal use of inhalers, i.e. inhaler handling errors, insufficient peak inspiratory flow or inappropriate inhaler. Secondary outcomes will also include length of hospital stay and 30-day readmission rate.

Study Overview

Study Type

Interventional

Enrollment (Actual)

101

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Admission to the HFR Fribourg internal medicine department
  2. Age greater than or equal to 18 years
  3. Diagnosis of COPD
  4. Use of an inhaler device for the treatment of COPD before admission

Exclusion Criteria:

  1. Inability to complete initial assessment due to language problems
  2. Inability to complete initial assessment due to physical or mental conditions
  3. Patient who has already received the intervention during a previous hospitalization.
  4. Length of hospitalization of less than 72 hours
  5. Patient already included in the control period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control cohort
Participants in the control cohort received standard care.
Active Comparator: Cohort with intervention
Participants included in the intervention cohort receive a systematic and standardised assessment of their inhaler on admission to our department. Their inhalers are adapted in accordance with a prescribing guide.
Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of inhalers used sub-optimally at hospital discharge
Time Frame: This outcome is assessed within 48 hours prior to hospital discharge
An inhaler used sub-optimally is defined as an inhaler used with at least one critical error and/or with insufficient inspiratory flow.
This outcome is assessed within 48 hours prior to hospital discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of inhaler used with a critical error at hospital discharge
Time Frame: This outcome is assessed within 48 hours prior to hospital discharge
In accordance with the literature, the investigators define critical error as an action or an inaction that in itself would have a detrimental impact of the delivery of the drug to the distal airways.
This outcome is assessed within 48 hours prior to hospital discharge
Proportion of inhaler used with suboptimal peak inspiratory flow at hospital discharge.
Time Frame: This outcome is assessed within 48 hours prior to hospital discharge
The peak inspiratory flow values considered sub-optimal for inhaler use are defined in the literature and are specific to each inhaler type.
This outcome is assessed within 48 hours prior to hospital discharge
Proportion of inhalers that cannot be handled properly despite appropriate teaching at hospital discharge.
Time Frame: This outcome is assessed within 48 hours prior to hospital discharge
If critical errors are identified in the handling of the inhaler, the physiotherapist provides targeted instruction to correct these errors. After each instruction, a new assessment of the inhaler technique is performed and the instruction is repeated if a critical error persists. If handling critical errors persist despite appropriate instruction, it's considered that the inhaler cannot be handled by the patient.
This outcome is assessed within 48 hours prior to hospital discharge
Proportion of inappropriate inhaler at hospital discharge.
Time Frame: This outcome is assessed within 48 hours prior to hospital discharge
An inhaler is considered unsuitable if the patient is unable to handle it properly after appropriate instruction and/or if the patient does not have sufficient inspiratory flow for optimal use of the inhaler.
This outcome is assessed within 48 hours prior to hospital discharge
Proportion of inhalers used sub-optimally at hospital discharge by type of inhaler.
Time Frame: This outcome is assessed within 48 hours prior to hospital discharge
The proportion of inhalers used sub-optimally at hospital discharge is described by type of inhaler.
This outcome is assessed within 48 hours prior to hospital discharge
Proportion of patients using at least one inhaler sub-optimally
Time Frame: This outcome is assessed within 48 hours prior to hospital discharge
A participant is considered to have suboptimal device use if making a critical error when using an inhaler or if their peak inspiratory flow rate is insufficient for optimal device use.
This outcome is assessed within 48 hours prior to hospital discharge
Length of hospital stay
Time Frame: This outcome is assessed up to three months
The length of stay in acute care on the internal medicine department will be documented.
This outcome is assessed up to three months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gaël Grandmaison, Dr, Hôpital Fribourgeois

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2022

Primary Completion (Actual)

December 25, 2022

Study Completion (Actual)

January 24, 2023

Study Registration Dates

First Submitted

December 29, 2021

First Submitted That Met QC Criteria

January 13, 2022

First Posted (Actual)

January 26, 2022

Study Record Updates

Last Update Posted (Estimate)

January 26, 2023

Last Update Submitted That Met QC Criteria

January 24, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on Systematic and standardised assessment of inhalers and implementation of a prescribing guide

3
Subscribe